Navidea raises $2.5M, valuing disease-hunting Macrophage subsidiary at $500M

Story excerpt provided by Columbus Business First.

Written by Carrie Ghose.

Navidea Biopharmaceuticals Inc. is raising $2.5 million in a funding round led by the former principal of its largest institutional investor in a deal that places the valuation of its new disease-hunting subsidiary at $500 million.

Click here to read the complete article.

Originally published January 21, 2015.